首页> 美国卫生研究院文献>Journal of Ophthalmology >Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

【2h】

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

机译：雷珠单抗初始治疗持续性糖尿病性黄斑水肿后玻璃体内阿柏西普和雷珠单抗的比较

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose To compare the visual and anatomic outcomes in patients with persistent diabetic macular edema (DME) who switched from ranibizumab to aflibercept with those who continued with previous ranibizumab therapy.

机译：目的比较持续性糖尿病人黄斑水肿（DME）从兰尼单抗转为aflibercept的患者与先前接受兰尼单抗治疗的患者的视觉和解剖结局。

著录项

期刊名称 Journal of Ophthalmology
作者
Ali Demircan; Zeynep Alkin; Ceren Yesilkaya; Gokhan Demir; Burcu Kemer;
展开▼
作者单位

展开▼
年(卷),期 2018(2018),-1
年度 2018
页码 4171628
总页数 5
原文格式 PDF
正文语种
中图分类眼科学;
关键词

相似文献

外文文献
中文文献
专利

1. Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema [J] . Ali Demircan, Zeynep Alkin, Ceren Yesilkaya, Journal of Ophthalmology . 2018,第1期

机译：雷珠单抗初始治疗持续性糖尿病性黄斑水肿后玻璃体内阿柏西普和雷珠单抗的比较
2. Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: ROTATED Trial 52 Week Results [J] . Taylor Caitlen, Frazier Heather, Rex Priscila, Investigative ophthalmology & visual science . 2019,第9期

机译：用Bevacizumab和/或Ranibizumab治疗后，玻术术治疗后的玻术AfliBercept（IAI）用于持续糖尿病性黄斑（DME）：旋转试验52周结果
3. Intravitreal Aflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) after Treatment with Bevacizumab and/or Ranibizumab: 6-Month ROTATED Trial Results [J] . Marcus Dennis M., Frazier Heather, Rex Priscila, Investigative ophthalmology & visual science . 2018,第9期

机译：用Bevacizumab和/或Ranibizumab治疗后玻术患者玻璃体糖尿病（IAI）用于持续糖尿病黄斑水肿（DME）：6个月的旋转试验结果
4. Morphology of vascular network in eyes with diabetic macular edema varies based on tolerance of aflibercept treatment interval length: preliminary findings [C] . Prateek Prasanna, Justis Ehlers, Nathaniel Braman, Biomedical Applications in Molecular, Structural, and Functional Imaging . 2019

机译：患有糖尿病黄斑水肿的眼睛中血管网络的形态基于AfliBercept治疗间隔长度的耐受性因耐受性而变化：初步调查结果
5. Characterizing response patterns to ranibizumab therapy in patients with wet age-related macular degeneration: A latent class growth analysis [D] . Sun, Diana 2015

机译：潮湿年龄相关性黄斑变性患者的ranibizumab治疗的表征反应模式：潜在的增长分析
6. Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with Treat-and-Extend Regimen—Its Usefulness and Problems [O] . Shinichiro Chujo, Masahiko Sugimoto, Taku Sasaki, 2020

机译：对玻璃体内雷尼兹省和玻璃体内嗜睡水肿的2年成果的比较治疗和延伸方案 - 其有用和问题
7. Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema [O] . Ali Demircan, Zeynep Alkin, Ceren Yesilkaya, 2018

机译：在持续糖尿病黄斑水肿中初始治疗后术术术后术治疗术后术治疗术后术治疗

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema

摘要

著录项

相似文献

相关主题

期刊订阅